蛋白磷酸酶2A与肿瘤发生发展关系的研究进展

doi:10.13481/j.1671-587X.20250229

Abstract

Abstract:

Protein phosphatase 2A（PP2A） is one of the major serine-threonine protein phosphatases in mammalian cells which plays an important role in regulating biological activities such as cellular mitosis and protein dephosphorylation. PP2A acts as a tumor suppressor and has been demonstrated to be genetically altered or functionally inactivated in a variety of solid cancers and leukemias， and its activity is inhibited， leading to subsequent proliferation of tumor cells. Clinical studies have shown that endogenous inhibitors such as SET， cancerous inhibitor of PP2A（CIP2A） and protein phosphatase methylesterase-1（PME-1） may reduce PP2A activity， which could be important indicators of tumor progression or recurrence. On the other hand， PP2A-activating drugs （e.g.FTY720） can restore the tumor-suppressing activity of PP2A by altering the structure of the inhibitor SET， thus effectively inhibiting tumor development. Therefore， PP2A and its inhibitors may serve as potential therapeutic targets in clinic. This article provides a comprehensive review on the mechanism of action of PP2A and its inhibitors in the pathogenesis of malignant tumor as well as their applications in oncotherapy， aiming to provide new directions for the treatment of malignant tumors.

Key words: Protein phosphatase 2A, Endogenous inhibitor, Tumor, Cancerous inhibitor of protein phosphatase 2A, Protein phosphatase methylesterase-1

CLC Number:

R730.2

Huiling ZHANG,Wenxiu GUO,Jun MENG. Research progress in relationship between protein phosphatase 2A and occurrence and development of tumor[J].Journal of Jilin University(Medicine Edition), 2025, 51(2): 534-540.

Figures/Tables 1

Tab.1

PP2A subunits and their binding proteins"

Subunit

Gene

Aliases （isoforms）

Structural

PPP2R1A

PPP2R1B

PR65α（Aα）

PR65β（Aβ）

PP2A_B

PP2A_B'

PPP2R2A

PPP2R2B

PPP2R2C

PPP2R2D

PPP2R5A

PPP2R5B

PPP2R5C

PPP2R5D

PPP2R5E

B55α，PR55α（Bα）

B55β，PR55β（Bβb）

B55γ，PR55γ1（Bγ）

B55δ，PR55δ（Bδ）

B56α，PR61α（Bα）

B56β，PR61β（Bβ）

B56γ，PR61γ（Bγ1，Bγ2，Bγ3）

B56δ，PR61δ（Bδ）

B56ε，PR61ε（Bε)

PP2A_B

″

PPP2R3A

PPP2R3B

PPP2R3C

B130，PR130（Bα1）； B72

PR72（Bα2）

PR48（Bβ1，Bβ2）

G5PR（Bγ）

PP2A_B

?

STRN，STRN3

PR110，PR93

PP2A_C

PPP2CA

PPP2CB

PP2Aα（Cα）

PP2Aβ（Cβ）

Tab.1

References 50

1	LIU X Y， XIAO W D， ZHANG Y N， et al. Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function［J］. Proc Natl Acad Sci USA， 2020， 117（1）： 328-336.
2	DAY E K， SOSALE N G， LAZZARA M J. Cell signaling regulation by protein phosphorylation： a multivariate， heterogeneous， and context-dependent process［J］. Curr Opin Biotechnol， 2016， 40： 185-192.
3	ROLDÁN M， NOLASCO G A， ARMENGOL L， et al. Advanced optical microscopy： unveiling functional insights regarding a novel PPP2R1A variant and its unreported phenotype［J］. Int J Mol Sci， 2023， 24（18）： 13699.
4	WANG L， YIN Y L， LIU X Z， et al. Current understanding of metal ions in the pathogenesis of Alzheimer’s disease［J］. Transl Neurodegener， 2020， 9： 10.
5	燕飞，黄南渠，金凤. 蛋白磷酸酶2A对微管相关蛋白tau的作用在阿尔茨海默病中的研究进展［J］. 遵义医科大学学报， 2020， 43（3）： 390-404.
6	SERGIENKO N M， DONNER D G， DELBRIDGE L M D， et al. Protein phosphatase 2A in the healthy and failing heart： new insights and therapeutic opportunities［J］. Cell Signal， 2022， 91： 110213.
7	MAZHAR S， TAYLOR S E， SANGODKAR J， et al. Targeting PP2A in cancer： Combination therapies［J］. Biochim Biophys Acta Mol Cell Res， 2019， 1866（1）： 51-63.
8	VAINONEN J P， MOMENY M， WESTERMARCK J. Druggable cancer phosphatases［J］. Sci Transl Med， 2021， 13（588）： eabe2967.
9	ULLAH R， YIN Q， SNELL A H， et al. RAF-MEK-ERK pathway in cancer evolution and treatment［J］. Semin Cancer Biol， 2022， 85： 123-154.
10	SANDAL P， JONG C J， MERRILL R A， et al. Protein phosphatase 2A-structure， function and role in neurodevelopmental disorders［J］. J Cell Sci， 2021， 134（13）： jcs248187.
11	YU H， ZAVERI S， SATTAR Z， et al. Protein phosphatase 2A as a therapeutic target in pulmonary diseases［J］. Medicina（Kaunas）， 2023， 59（9）： 1552.
12	FOWLE H， ZHAO Z R， GRAÑA X. PP2A holoenzymes， substrate specificity driving cellular functions and deregulation in cancer［J］. Adv Cancer Res， 2019， 144： 55-93.
13	CHO U S， XU W Q. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme［J］. Nature， 2007， 445（7123）： 53-57.
14	SANGODKAR J， FARRINGTON C C， MCCLINCH K， et al. All roads lead to PP2A： exploiting the therapeutic potential of this phosphatase［J］. FEBS J， 2016， 283（6）： 1004-1024.
15	SLUPE A M， MERRILL R A， STRACK S. Determinants for substrate specificity of protein phosphatase 2A［J］. Enzyme Res， 2011， 2011： 398751.
16	GRECH G， BALDACCHINO S， SALIBA C， et al. Deregulation of the protein phosphatase 2A， PP2A in cancer： complexity and therapeutic options［J］. Tumour Biol， 2016， 37（9）： 11691-11700.
17	EICHHORN P J A， CREYGHTON M P， BERNARDS R. Protein phosphatase 2A regulatory subunits and cancer［J］. Biochim Biophys Acta， 2009， 1795（1）： 1-15.
18	PERIS I， ROMERO-MURILLO S， VICENTE C， et al. Regulation and role of the PP2A-B56 holoenzyme family in cancer［J］. Biochim Biophys Acta Rev Cancer， 2023， 1878（5）： 188953.
19	FÉLIX M A， COHEN P， KARSENTI E. Cdc2 H1 kinase is negatively regulated by a type 2A phosphatase in the Xenopus early embryonic cell cycle： evidence from the effects of okadaic acid［J］. EMBO J， 1990， 9（3）： 675-683.
20	GOGUET-RUBIO P， AMIN P， AWAL S， et al. PP2A-B55 holoenzyme regulation and cancer［J］. Biomolecules， 2020， 10（11）： 1586.
21	SABLINA A A， HECTOR M， COLPAERT N， et al. Identification of PP2A complexes and pathways involved in cell transformation［J］. Cancer Res， 2010， 70（24）： 10474-10484.
22	TOMIYAMA A， KOBAYASHI T， MORI K， et al. Protein phosphatases-a touchy enemy in the battle against glioblastomas： a review［J］. Cancers （Basel）， 2019， 11（2）： 241.
23	DEDOBBELEER M， WILLEMS E， FREEMAN S， et al. Phosphatases and solid tumors： focus on glioblastoma initiation， progression and recurrences［J］. Biochem J， 2017， 474（17）： 2903-2924.
24	KASHANI E， VASSELLA E. Pleiotropy of PP2A phosphatases in cancer with a focus on glioblastoma IDH wildtype［J］. Cancers （Basel）， 2022， 14（21）： 5227.
25	CLARK A R， OHLMEYER M. Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration［J］. Pharmacol Ther， 2019， 201： 181-201.
26	GADEK J E， KLEIN H G， HOLLAND P V， et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects［J］. J Clin Invest， 1981， 68（5）： 1158-1165.
27	RUEDIGER R， RUIZ J， WALTER G. Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice［J］. Mol Cell Biol， 2011， 31（18）： 3832-3844.
28	GUO S， YANG J， WU M， et al. Clinical value screening， prognostic significance and key pathway identification of miR-204-5p in endometrial carcinoma： a study based on the Cancer Genome Atlas （TCGA）， and bioinformatics analysis［J］. Pathol Res Pract， 2019， 215（5）： 1003-1011.
29	REMMERIE M， JANSSENS V. PP2A： a promising biomarker and therapeutic target in endometrial cancer［J］. Front Oncol， 2019， 9： 462.
30	GIBSON W J， HOIVIK E A， HALLE M K， et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis［J］. Nat Genet， 2016， 48（8）： 848-855.
31	WANDZIOCH E， PUSEY M， WERDA A， et al. PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells［J］. Cancer Res， 2014， 74（16）： 4295-4305.
32	LIANG X J， BAO X F， CHEN G L. SET protein in cancer： a potential therapeutic target［J］. Mini Rev Med Chem， 2021， 21（16）： 2290-2299.
33	ZHANG W P， CAI J X， CHEN S Y， et al. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway［J］. Mol Med Rep， 2015， 12（1）： 1506-1514.
34	YAZDI A， GHASEMI-KASMAN M， JAVAN M. Possible regenerative effects of fingolimod （FTY720） in multiple sclerosis disease： an overview on remyelination process［J］. J Neurosci Res， 2020， 98（3）： 524-536.
35	DE PALMA R M， PARNHAM S R， LI Y T， et al. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction［J］. FASEB J， 2019， 33（6）： 7647-7666.
36	O’CONNOR C M， PERL A， LEONARD D， et al. Therapeutic targeting of PP2A［J］. Int J Biochem Cell Biol， 2018， 96： 182-193.
37	DE P， CARLSON J H， LEYLAND-JONES B， et al. Role of “oncogenic nexus” of CIP2A in breast oncogenesis： how does it work？［J］. Am J Cancer Res， 2015， 5（9）： 2872-2891.
38	VAARALA M H， VÄISÄNEN M R， RISTIMÄKI A. CIP2A expression is increased in prostate cancer［J］. J Exp Clin Cancer Res， 2010， 29（1）： 136.
39	JUNTTILA M R， PUUSTINEN P， NIEMELÄ M， et al. CIP2A inhibits PP2A in human malignancies［J］. Cell， 2007， 130（1）： 51-62.
40	PAVIC K， GUPTA N， OMELLA J D， et al. Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A［J］. Nat Commun， 2023， 14： 1143.
41	MANNAVA S， OMILIAN A R， WAWRZYNIAK J A， et al. PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells［J］. Oncogene， 2012， 31（12）： 1484-1492.
42	LI Y T， BALAKRISHNAN V K， ROWSE M， et al. Coupling to short linear motifs creates versatile PME-1 activities in PP2A holoenzyme demethylation and inhibition［J］. eLife， 2022， 11： e79736.
43	XING Y N， LI Z， CHEN Y， et al. Structural mechanism of demethylation and inactivation of protein phosphatase 2A［J］. Cell， 2008， 133（1）： 154-163.
44	JACKSON J B， PALLAS D C. Circumventing cellular control of PP2A by methylation promotes transformation in an Akt-dependent manner［J］. Neoplasia， 2012， 14（7）： 585-599.
45	GUFFENS L， DERUA R， JANSSENS V. PME-1 sensitizes glioblastoma cells to oxidative stress-induced cell death by attenuating PP2A-B55α-mediated inactivation of MAPKAPK2-RIPK1 signaling［J］. Cell Death Discov， 2023， 9（1）： 265.
46	BI L， XIE C L， YAO M， et al. The histone chaperone complex FACT promotes proliferative switch of G₀ cancer cells［J］. Int J Cancer， 2019， 145（1）： 164-178.
47	COLIAT P， RAMOLU L， JÉGU J， et al. Constitutive or induced HIF-2 addiction is involved in resistance to anti-EGFR treatment and radiation therapy in HNSCC［J］. Cancers （Basel）， 2019， 11（10）： 1607.
48	CHUNG V， MANSFIELD A S， BRAITEH F， et al. Safety， tolerability， and preliminary activity of LB-100， an inhibitor of protein phosphatase 2A， in patients with relapsed solid tumors： an open-label， dose escalation， first-in-human， phase I trial［J］. Clin Cancer Res， 2017， 23（13）： 3277-3284.
49	LEI X， MA N， DU L H， et al. PP2A and tumor radiotherapy［J］. Hereditas， 2020， 157（1）： 36.
50	ZHANG D M， FU M J， LI L Y， et al. PKC-δ attenuates the cancer stem cell among squamous cell carcinoma cells through down-regulating p63［J］. Pathol Res Pract， 2017， 213（9）： 1119-1124.

[1]	Wenchang CAI,Yuqi LIU,Han WANG,Helin WANG,Zhenjiang WANG,Zishen XIAO,Shiyuan MA,Liping AN,Yanbo LIU. Expression of protein kinase D2 in bladder cancer tissue and its effect on tumor immune microenvironment [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 378-391.
[2]	Xiao WANG,Chanyu XIONG,Yun ZHANG,Juanjuan JI,Yu ZHOU. Sequencing of whole exon hybridization capture genes of TP53 and KRAS mutations in patients with common digestive system tumors and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 471-478.
[3]	Xin ZHANG,Fei WANG,Bingjie CUI,Jing DU. Research progress in effect of phosphorylation modification of Hedgehog signaling pathway on occurrence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 526-533.
[4]	Luyao WANG,Chenxi ZHAO,Wanze ZHANG,Linlin LIU. Second primary tracheal adenoid cystic carcinoma:A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 215-221.
[5]	Shuo ZHANG,Yunxiu XIA,Weiwei CHEN,Hongliang DONG,Bingjie CUI,Cuilan LIU,Zhiqiang LIU,Fei WANG,Jing DU. Effect of over-expression of NR2F2 on biological behaviors of human ovarian cancer SKOV3 cells [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 58-67.
[6]	Fengjiao WANG,Chao GU,Sha HU,Qin FENG,Rujuan ZHENG,Zengyan ZHU,Wenjuan WANG. Effect of low dose of methotrexate combined with sorafenib on osteosarcoma xenografts of mice and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 9-16.
[7]	Jingshun ZHANG,Yinggang ZOU,Lianwen ZHENG. Effect of over-expression SLC7A5 on apoptosis of ovarian granulosa cells in rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1526-1534.
[8]	Bin ZHAO,Jinye YANG,Zhiyao LI,Chengwei BI,Libo YANG,Zhiyu SHI,Xin LI,Jianpeng ZHANG,Yuanlong SHI,Yong YANG,Guoying ZHANG. Inhibitory effect of miR-30c-5p on proliferation, migration, and invasion of prostate cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1632-1643.
[9]	Xi YANG,Qin YUAN,Lan YANG,Wenjie ZHANG. Bioinformatics analysis on PDE1B expression and prognosis of gastric cancer and tumor microenvironment [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1664-1676.
[10]	Yanyan LU,Xiangbo XU,Yamei WU,Yuqi LIU,Han WANG,Lijuan YANG,Zhenjiang WANG,Zishen XIAO,Yanbo LIU. Eosinophil infiltration in cervical lesion and cervical cancer tissues and their clinical significances [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1691-1702.
[11]	Yuxiao SHI,Meilan LIU,Meilin ZHU,Feng WEI. Effects of 5-Aza-CdR on autophagy and apoptosis of papillary thyroid cancer cells in subcutaneous xenograft tumor tissue of nude mice and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1330-1338.
[12]	Honghong LI,Na YU,Minghao SHI,Ying SUN,Yao LI,Zhongjun SHEN,Xiaoyi LIU,Liyan ZHAO. Predictive value of new thrombotic risk assessment model for venous thromboembolism in patients with malignant tumors [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1390-1399.
[13]	Wenhui LIU,Miao YU,Ying GUO,Yupeng LIU,Yang XING,Xinyu HONG,Jiale CUI. Research progress in effect of CXC chemokine receptor 3 on occurrence and development of nervous system diseases [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1474-1480.
[14]	Yuanguo WANG,Peng ZHANG. Bioinformatics analysis based on relationship between SSP1 and TGFB1 and occurrence, prognosis, and immune invasion of esophageal adenocarcinoma [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1076-1086.
[15]	Yilin REN,Yichen ZANG,Lele XUE,Kaige YANG,Sufang CHEN,Weinan WANG,Chenghua LUO,Weihua LIANG,Lianghai WANG,Feng LI,Jianming HU. Bioinformatics analysis based on effect of M2 macrophage-derived Siglec15 on malignant biological behaviour of esophageal squamous cell carcinoma cells and its experimental validation [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 881-890.

Research progress in relationship between protein phosphatase 2A and occurrence and development of tumor

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 50

Related Articles 15

Metrics

Comments

Recommended 0